AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03190031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance inspiratory muscle training
Description: Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
Study NCT01707264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: Monoclonal antibody administered by intravenous infusion every 28 days.
Study NCT04271865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Education
Description: Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
Study NCT04271865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: model nutrition kitchen
Description: Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
Study NCT04271865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: recipe book
Description: 3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
Study NCT00987779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
Study NCT00987779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
Study NCT04583189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Performance of the test antigenic and test RT-PCR
Description: Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
Study NCT02803658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking behavior
Study NCT02803658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking behavior
Study NCT02803658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sperm collection
Study NCT01165528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: type of mechanical ventilation
Description: patients are randomized to receive one of the two types of mechanical ventilation for ARDS
Study NCT01428336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 250 ug ACTH stimulation test
Description: ACTH stimulation test will be done using 250 ug cortrosyn dose
Study NCT02315274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent remote contact between clinic visits.
Description: Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
Study NCT03523299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
Study NCT00456300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
Study NCT00456300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Each subject received a baseline study with insulin alone
Study NCT00456300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Each subject received a baseline study with insulin alone
Study NCT00727597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 600mg
Description: QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
Study NCT00727597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted Lexiva
Description: Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
Study NCT01905436 — intervention group
Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
Study NCT00373633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: Gold standard for post thoracotomy pain
Study NCT00373633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural Intercostal Catheter
Description: Continuous extra-pleural intercostal local anesthesia
Study NCT02489344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ/SAR402671
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT00798044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other: quality improvement feedback system
Description: Surveys patients regarding treatment experiences.
Study NCT00798044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Feedback
Description: Weekly feedback reports provided to counselors
Study NCT00366158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: St. Jude Medical Victory dual-chamber pacemaker
Description: Pacemaker implant
Study NCT03438292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
Study NCT01428336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 ug Cortrosyn stimulation test
Description: ACTH stimulation test using a 25 ug cortrosyn dose
Study NCT04271865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Provision of Dates
Description: Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females
Study NCT01428336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin tolerance test
Description: subjects will undergo an insulin tolerance test
Study NCT02230371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
Study NCT02230371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
Study NCT00620152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1
Description: Low glycemic load diet by telephone counseling
Study NCT00620152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2
Description: Low fat diet by telephone counseling
Study NCT01855152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised WHELD intervention
Description: Experimental: Optimised WHELD intervention
Study NCT01855152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment delivered as usual in the care home
Study NCT02317952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula
Study NCT02317952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Formula
Study NCT01519739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediGuide™
Description: MediGuide™ system will be used to guide CRT implants
Study NCT00366158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: St. Jude Medical Victory dual-chamber pacemaker
Description: Pacemaker implant
Study NCT00366158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventricular Intrinsic Preference
Description: Programming of pacemaker
Study NCT00366158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular Intrinsic Preference
Description: Programming of pacemaker
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788
Description: This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Study NCT03793010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single Intra-articular injection
Study NCT02660073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES+FES
Description: 12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
Study NCT02660073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control+FES
Description: 12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
Study NCT02616328 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study NCT00939146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outlook Attention Control
Description: Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
Study NCT00939146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outlook Intervention
Description: The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
Study NCT04669106 — intervention group
Intervention type: OTHER
Intervention: laboratory clinical trial study
Description: The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
Study NCT01622049 — intervention group
Intervention type: DEVICE
Intervention: Selective Laser Photocoagulation of Communicating Vessels
Description: Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
Study NCT00910962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: 7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Study NCT00910962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: 15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Study NCT00910962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01813630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-3002
Study NCT01813630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin®
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-600mg
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-600mg
Description: Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
Study NCT02580227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-400mg
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-400mg
Description: Phase I: oral LDE225 (Sonidegib), 400mg daily.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225-800mg
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.
Study NCT01431794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225-800mg
Description: Phase I: oral LDE225 (Sonidegib), 800mg daily.
Study NCT00736385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage (Metformin)
Description: metformin XR 2000 mg daily for 12 months
Study NCT00736385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2000 mg daily for 12 months
Study NCT03267511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study NCT02580227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
Study NCT02131519 — intervention group
Intervention type: PROCEDURE
Intervention: internal jugular vein catheter placement
Study NCT03554980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied with a brush.
Study NCT03554980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride varnish
Description: NaF will be applied with a brush
Study NCT01355796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
Study NCT01355796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
Study NCT01355796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Study NCT01355796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: 4 ml of 7 % saline aerosolized twice a day for 2 weeks
Study NCT03379142 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Faith-Based messages
Description: We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
Study NCT06508879 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aquacel Ag Surgical®
Description: Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
Study NCT06508879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (sterile gauze and adhesive tape)
Description: Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.